Thursday, September 24 - EST (Eastern Time, UTC-05:00
Thursday, September 24 - EST (Eastern Time, UTC-05:00
6:45am - 7:45am60 mins
Biotech Week Boston 2026 Fun Run
8:00am - 8:30am30 mins
Registration
8:30am - 8:35am5 mins
Oligo-based Therapeutics: Translational & Enabling Platforms
Chair Remarks
8:30am - 8:35am5 mins
mRNA & Next-Gen RNA: Translational & Enabling
Chair Remarks
8:30am - 8:45am15 mins
Business Forum
Innovation Presentation: Pioneering taRNA Therapies for Infectious Disease and Beyond
- Cory Sago - CEO, Amplitude Therapeutics
8:35am - 9:00am25 mins
Oligo-based Therapeutics: Translational & Enabling Platforms
From RNA Target Biology to Candidate Selection: AI-Guided LNA Oligonucleotide Design for Extrahepatic Therapeutics
- Anders Näär - Professor of Metabolic Biology, UC Berkeley
8:35am - 9:00am25 mins
mRNA & Next-Gen RNA: Translational & Enabling
Harnessing In-Cell Selection For Small Molecule RNA Targeting
- Kevin Weeks - Kenan Distinguished Professor of Chemistry, UNC Chapel Hill
8:45am - 9:00am15 mins
Business Forum
Innovation Presentation: Pioneering delivery of antibody-oligo conjugates to treat neurological diseases
- David Hardwicke - Co-Founder, Aerska
9:00am - 9:25am25 mins
Oligo-based Therapeutics: Translational & Enabling Platforms
Rapid Development and First-in-Human Treatment of GBFsen, a Patient-Specific Antisense Oligonucleotide Therapy for familial TDP-43 Amyotrophic Lateral Sclerosis
- Tamar Grossman - CEO, La Jolla Labs
9:00am - 9:25am25 mins
mRNA & Next-Gen RNA: Translational & Enabling
Programmable snoRNA-mediated Protein Localization Inside and Outside Cells
- Tao Pan - Professor of Biochemistry & Molecular Biology, Univerity of Chicago
9:00am - 9:15am15 mins
Business Forum
Innovation Presentation: Exploring First-In-Class Re-Dosable circRNA For Rare Metabolic Disease
- Bakhtyar Ali - CEO, Amrixa Pharmaceuticals
9:15am - 9:30am15 mins
Business Forum
APEXm™ (Amplified and Prolonged EXpression mRNA) is a modular linear mRNA platform for potent and durable therapeutic protein expression
- David Weinberg - CEO, ParcelBio
9:25am - 9:50am25 mins
Oligo-based Therapeutics: Translational & Enabling Platforms
Building the Future of Precision RNA Medicine: Lessons from 50+ Treated Patients
- Konstantina Skourti-Stathaki - Vice President, ASO Discovery & Research, n-Lorem Foundation
9:25am - 9:50am25 mins
mRNA & Next-Gen RNA: Translational & Enabling
Leveraging Covalent Chemistry to Achieve RNA Selectivity
- Brittany Morgan - Professor, University of Notre Dame
9:30am - 9:45am15 mins
Business Forum
The Nanoprimer Platform: Unlocking Extrahepatic Delivery of RNA-based Therapeutics
- Matthieu Germain, PhD - Head of Chemistry, Nanobiotix
9:45am - 10:00am15 mins
Business Forum
Innovation Presentation: Selectivity Enabling NanoShell (SENS™): A Compendium of Innovative Lipid-Polymer Hybrid Nanoparticles Optimized for Robust Tissue-Selective Delivery of Diverse Payloads with Enhanced Stability, Tolerability and Low Immunogenicity.
- Natalia Ulyanova - ead of US Business and Development and Licensing, Samyang Biopharm USA
9:50am - 10:15am25 mins
Oligo-based Therapeutics: Translational & Enabling Platforms
Overcoming Challenges in Peptide-Oligonucleotide Conjugation (POC): From Lead Optimization through Scale-Up
- Jun Zhou - Senior Director, Oligonucleotide Medicinal Chemistry, WuXi TIDES
9:50am - 10:15am25 mins
mRNA & Next-Gen RNA: Translational & Enabling
Build Once, Run Many: An Adaptable IVT and Purification Platform for Next-Gen RNA
- Rok Sekirnik - Head Process Development mRNA/pDNA, Sartorius BIA Separations
10:00am - 10:15am15 mins
Business Forum
Innovation Presentation Opportunity Available
10:15am - 10:30am15 mins
Oligo-based Therapeutics: Translational & Enabling Platforms
Spotlight Presentation Opportunity Available
10:15am - 10:30am15 mins
mRNA & Next-Gen RNA: Translational & Enabling
Spotlight Presentation Opportunity Available
10:30am - 11:00am30 mins
Morning Break
11:00am - 11:25am25 mins
Oligo-based Therapeutics: Scaling & Delivery
Process Development and characterization of PMO for AOC drug candidate for Duchenne Dystrophy
- Mitch Martini - Associate Director, AOC Process Development & Manufacturing, Avidity Biosciences
11:00am - 11:25am25 mins
mRNA & Next-Gen RNA: Pre-Clinical Development
mRNA-based Immunotherapy for Adult Solid Tumors and Paediatric Sarcomas
- Randall Hyer - Chief Executive Officer, Merlin Biotech
11:00am - 12:00pm60 mins
Business Forum
Investor Insights: Question Circle
- Soyoung Park - General Partner, 1004 Venture Partners
- Max Colbert, MD, MBA - Senior Associate, Medical Excellence Capital
11:25am - 11:50am25 mins
Oligo-based Therapeutics: Scaling & Delivery
Translating and scaling ASOs with an AI platform
11:25am - 11:50am25 mins
mRNA & Next-Gen RNA: Pre-Clinical Development
Pioneering Durable Expression via Modified & Optimized saRNA Therapeutics
- Joshua McGee - CSO, Keylicon Biosciences
11:50am - 12:10pm20 mins
Oligo-based Therapeutics: Scaling & Delivery
Comprehensive Analytical Strategies in Oligo CMC: Navigating Complexity from Early Development to Final Release
11:50am - 12:10pm20 mins
mRNA & Next-Gen RNA: Pre-Clinical Development
Technology Presentation Opportunity Available
12:10pm - 12:50pm40 mins
Oligo-based Therapeutics: Delivery
Advancing Targeted Delivery Strategies for Oligonucleotide & Next-Gen RNA Therapeutics
- Vadim Dudkin, PhD - Founding Chief Technology Officer, Soufflé Therapeutics
- Ranjan Batra - CSO, Dyne Therapeutics
- Annette Bak, Ph.D. - Head of Advanced Drug Delivery, AstraZeneca
12:10pm - 12:50pm40 mins
mRNA & Next-Gen RNA: Pre-Clinical Development
Circular RNA -The Next Frontier in RNA Therapeutics
- Peter Weinstein - CEO, Circurna
- Lubor Gaal - CFO, Circio AB
- Anna-Rose Welch - Editorial and Community Director Advancing RNA, Life Science Connect
12:50pm - 2:00pm70 mins
Lunch
2:00pm - 2:05pm5 mins
Oligo-based Therapeutics: Delivery
Chair Remarks
2:00pm - 2:05pm5 mins
mRNA & Next-Gen RNA: Delivery
Chair Remarks
2:00pm - 3:00pm60 mins
Business Forum
Pharma Insights Question Circle
- Elena Diez Cecilia - Senior Director External Innovation DPDS, Johnson & Johnson
- Shaan Gandhi - VP and Head of Partnerships, PAVE, Pfizer
- Maj Petersen, PhD - Senior Director of Innovation and Project Execution, Novo Nordisk
2:05pm - 2:30pm25 mins
Oligo-based Therapeutics: Delivery
Targeted Delivery of Oligonucleotides for Neuromuscular Diseases
- Ranjan Batra - CSO, Dyne Therapeutics
2:05pm - 2:30pm25 mins
mRNA & Next-Gen RNA: Delivery
Utilising Large Language Models for mRNA Design and Property Optimization
- Sizhen Li - Computational Science Lead, Sanofi
2:30pm - 2:55pm25 mins
Oligo-based Therapeutics: Delivery
Extra-hepatic delivery of oligonucleotide conjugates: a preclinical development perspective
- Pedro Morais - Preclinical Development Lead DMPK, Bayer
2:30pm - 2:55pm25 mins
mRNA & Next-Gen RNA: Delivery
Pioneering Stabilized Nanoparticles For mRNA Multiroute Delivery
- Philipp Schreppel - Senior Director Business Development, Ethris
2:55pm - 3:20pm25 mins
Oligo-based Therapeutics: Delivery
Innovating targeted oligonucleotide delivery with enhanced cell and tissue specificity
- Jim Weterings - VP Head of Oligo Discovery, Bonito Sciences
2:55pm - 3:20pm25 mins
mRNA & Next-Gen RNA: Delivery
Presentation: Optimizing mRNA delivery with targeted LNPs for muscle, bone marrow, and immune cell therapies
3:20pm - 3:45pm25 mins
Oligo-based Therapeutics: Delivery
Technology Presentation Opportunity Available
3:20pm - 3:45pm25 mins
mRNA & Next-Gen RNA: Delivery
Get the edge in nanomedicine formulation and characterization
- Ben Knappett - Sr. Product Manager - Sunny Suite, Unchained Labs
3:45pm - 4:30pm45 mins
Afternoon Break
4:30pm - 5:30pm60 mins
Roundtables
Round Tables
- Yacoub Habib - CEO, Ophidion, Inc.
- Praveen Kumar Pogula - Director, Drug Substance,, QurAlis
- Bao Cai, PhD - Executive Director, Process Development, Sarepta Therapeutics
4:30pm - 5:30pm60 mins
RNA Leaders Business Track
Partnering Hour
5:30pm - 6:00pm30 mins
Coaches to Networking Party
6:00pm - 9:30pm210 mins
Biotech Week Boston Party at the Museum of Science
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。